Read More Pharma Industry News Why VG801 could reshape endpoint strategy in inherited retinal disease development VG801 shows early vision gains in Stargardt disease. Discover how VeonGen Therapeutics is redefining endpoints and regulatory strategy. bySoujanya RaviMarch 28, 2026